Lechanteur Anna, Evrard Brigitte
Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, 4000 Liège, Belgium.
Pharmaceutics. 2020 Jan 9;12(1):55. doi: 10.3390/pharmaceutics12010055.
Although dry powder inhalers (DPIs) have attracted great interest compared to nebulizers and metered-dose inhalers (MDIs), drug deposition in the deep lung is still insufficient to enhance therapeutic activity. Indeed, it is estimated that only 10%-15% of the drug reaches the deep lung while 20% of the drug is lost in the oropharyngeal sphere and 65% is not released from the carrier. The potentiality of the powders to disperse in the air during the patient's inhalation, the aerosolization, should be optimized. To do so, new strategies, in addition to classical lactose-carrier, have emerged. The lung deposition of carrier-free particles, mainly produced by spray drying, is higher due to non-interparticulate forces between the carrier and drug, as well as better powder uniformity and aerosolization. Moreover, the association of two or three active ingredients within the same powder seems easier. This review is focused on a new type of carrier-free particles which are characterized by a sugar-based core encompassed by a corrugated shell layer produced by spray drying. All excipients used to produce such particles are dissected and their physico-chemical properties (Péclet number, glass transition temperature) are put in relation with the lung deposition ability of powders. The importance of spray-drying parameters on powders' properties and behaviors is also evaluated. Special attention is given to the relation between the morphology (characterized by a corrugated surface) and lung deposition performance. The understanding of the closed relation between particle material composition and spray-drying process parameters, impacting the final powder properties, could help in the development of promising DPI systems suitable for local or systemic drug delivery.
尽管与雾化器和定量吸入器(MDIs)相比,干粉吸入器(DPIs)已引起了极大的关注,但药物在肺深部的沉积仍不足以增强治疗活性。实际上,据估计只有10%-15%的药物能到达肺深部,而20%的药物在口咽区域丢失,65%的药物未从载体中释放出来。粉末在患者吸入过程中在空气中分散的潜力,即雾化,应加以优化。为此,除了传统的乳糖载体外,还出现了新的策略。无载体颗粒主要通过喷雾干燥产生,由于载体与药物之间不存在颗粒间作用力,以及更好的粉末均匀性和雾化效果,其在肺部的沉积更高。此外,在同一粉末中联合两种或三种活性成分似乎更容易。本综述聚焦于一种新型的无载体颗粒,其特征是具有由喷雾干燥产生的波纹壳层包裹的糖基核心。剖析了用于生产此类颗粒的所有辅料,并将它们的物理化学性质(佩克莱数、玻璃化转变温度)与粉末的肺部沉积能力联系起来。还评估了喷雾干燥参数对粉末性质和行为的重要性。特别关注了形态(以波纹表面为特征)与肺部沉积性能之间的关系。理解颗粒材料组成与喷雾干燥工艺参数之间的紧密关系,这会影响最终粉末的性质,有助于开发适用于局部或全身给药的有前景的DPI系统。